Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety

References

• Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010;2010(1):338–347.
   PubMedGoogle Scholar
• Auerbach M, DeLoughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):57–66.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008;83(7):580–588.
   PubMed Web of Science ®Google Scholar
• Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480–491.
   PubMed Web of Science ®Google Scholar
• Monofer (ferric derisomaltose). Summary of product characteristics. Pharmacosmos UK Ltd; Sep 2020.
   Google Scholar
• Monoferric (ferric derisomaltose). Product information. Pharmacosmos A/S; Jul 2020.
   Google Scholar
• Ferinject (ferric carboxymaltose). Summary of product characteristics. Vifor Pharma UK Ltd; Nov 2020.
   Google Scholar
• Injectafer (ferric carboxymaltose). Prescribing information. Vifor International, Inc; Sep 2020.
   Google Scholar
• Feraheme (ferumoxytol). Prescribing information. AMAG Pharmaceuticals, Inc; Sep 2020.
   Google Scholar
• European Medicines Agency. Public statement. Rienso: withdrawal of the marketing authorisation in the European Union. EMA/437901/2015; EMEA/H/C/2215. 10 Jul 2015. [cited 2021 Jan 27]. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-rienso-ferumoxytol-withdrawal-marketing-authorisation-european-union_en.pdf
   Google Scholar
• Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):529–535.
   PubMed Web of Science ®Google Scholar
• Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15(Suppl 2):S93–S98.
   PubMedGoogle Scholar
• Rottembourg J. The non-biologic-complex-drug concept. Int J Biopharm Sci. 2018;1(1):104.
   Google Scholar
• Borchard G, Flühmann B, Mühlebach S. Nanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol. 2012;64(2):324–328.
   PubMed Web of Science ®Google Scholar
• WO 2007/081744 A2 – Methods and compositions for administration of iron. International Application No. PCT/US2007/000176. International filing date: 2007 Jan 8; [cited 2021 Jan 27]. Available from: https://patents.google.com/patent/WO2007081744A2/en.
   Google Scholar
• US 9,376,505 B2 – Aqueous iron carbohydrate complexes, their production and medicaments containing them. Application No. 13/556,733. International filing date: 2012 Jul 24; [cited 2021 Jan 27]. Available from: https://patents.google.com/patent/US9376505B2/en.
   Google Scholar
• Sigma-Aldrich. Product Specification. Maltodextrin 4.0–7.0. Product Number: 419672. [cited 2020 Sep 17]. Available from: https://www.sigmaaldrich.com/catalog/substance/maltodextrin12345905036611?lang=en&region=GB.
   Google Scholar
• US 8,501,158 B2 – Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents. Application No. 12/963,308. Filing date: 2010 Dec 8; [cited 2021 Jan 27]. Available from: https://patents.google.com/patent/US8501158B2/en.
   Google Scholar
• US 8,895,612 B2 – Methods and compositions for administration of iron. Application No. 14/100,717. Filling date: 2013 Dec 9; [cited 2021 Jan 27]. Available from: https://patents.google.com/patent/US8895612B2/en.
   Google Scholar
• Neiser S, Rentsch D, Dippon U, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals. 2015;28(4):615–635.
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia 2017. Volume III. Jan 2017.
   Google Scholar
• De Belder AN. Dextran. © Amersham Biosciences AB 2003.
   Google Scholar
• Fütterer S, Andrusenko I, Kolb U, et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013;86:151–160.
   PubMed Web of Science ®Google Scholar
• Nikravesh N, Borchard G, Hofmann H, et al. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: from production to clinical practice. Nanomedicine. 2020;26:102178.
   PubMed Web of Science ®Google Scholar
• Sidhu PS, Gilkes RJ, Cornell RM, et al. Dissolution of iron oxides and oxyhydroxides in hydrochloric and perchloric acids. Clays Clay Miner. 1988;29(4):269–276.
   Google Scholar
• Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 2003;531(1–2):81–92.
   PubMed Web of Science ®Google Scholar
• Garbowski MW, Bansal S, Porter JB, et al. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020.
   PubMed Web of Science ®Google Scholar
• Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432–443.
   PubMed Web of Science ®Google Scholar
• Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93(5):683–690.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007–1014.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111–120.
   PubMed Web of Science ®Google Scholar
• Wolf M, Auerbach M, Kalra PA, et al. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96(1):E11–E15.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–195.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650–654.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Rapid response to BMJ. Re: pandemrix vaccine: why was the public not told of early warning signs. EMA/659264/2018. 2018 [cited 2021] Jan 27. Available from: https://www.ema.europa.eu/en/documents/other/european-medicines-agency-rapid-response-british-medical-journal-pandemrix_.pdf
   Google Scholar
• OCEBM Levels of evidence working group. The Oxford 2011 Levels of Evidence.
   Google Scholar
• Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
   PubMed Web of Science ®Google Scholar
• Lim W, Afif W, Knowles S, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. Vox Sang. 2019;114(4):363–373.
   PubMed Web of Science ®Google Scholar
• Achebe M, DeLoughery TG. Clinical data for intravenous iron – debunking the hype around hypersensitivity. Transfusion. 2020;60(6):1154–1159.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2016;89(1):28–39.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45(1):60–62.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015;172(21):5025–5036.
   PubMed Web of Science ®Google Scholar
• Gómez-Ramírez S, Shander A, Spahn DR, et al. Prevention and management of acute reactions to intravenous iron in surgical patients. Blood Transfus. 2019;17(2):137–145.
   PubMed Web of Science ®Google Scholar
• Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266–275.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Meindl E, Wagner S, et al. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphatemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside – a systematic review and meta‐analysis. Br J Clin Pharmacol. 2020.
   Web of Science ®Google Scholar
• Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag. 2020;16:245–259.
   PubMed Web of Science ®Google Scholar
• Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793–1803.
   PubMed Web of Science ®Google Scholar
• Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):e124486.
   PubMed Web of Science ®Google Scholar
• Wolf M, Schaefer B, Zoller H. Persistent hypophosphatemia after ferric carboxymaltose is associated with persistent changes in biomarkers of bone metabolism. Blood. 2020;136(Suppl 1):13–14.
   Google Scholar
• Iqbal TH, Wolf M, Schaffalitzky de Muckadell P, et al. PHOSPHARE studies: important changes in phosphate homeostasis and bone metabolism after IV iron. Poster presented at the British Society of Gastroenterology (BSG) Annual Meeting, Glasgow, 17–20 Jun, 2019.
   Google Scholar
• Emrich IE, Lizzi F, Siegel JD, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose – the randomized controlled HOMe aFers study. BMC Med. 2020;18(1):178.
   PubMed Web of Science ®Google Scholar
• Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397–406.
   PubMed Web of Science ®Google Scholar
• Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018;33(9):1628–1635.
   PubMed Web of Science ®Google Scholar
• Stöhr R, Sandstede L, Heine GH, et al. High-dose ferric carboxymaltose in patients with HFrEF induces significant hypophosphatemia. J Am Coll Cardiol. 2018;71(19):2270–2271.
   PubMed Web of Science ®Google Scholar
• Fang W, Kenny R, Rizvi QU, et al. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status. BMC Gastroenterol. 2020;20(1):183.
   PubMed Web of Science ®Google Scholar
• Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006;2(3):136–148.
   PubMedGoogle Scholar
• Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14(4):R147.
   PubMed Web of Science ®Google Scholar
• Gravelyn TR, Brophy N, Siegert C, et al. Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population. Am J Med. 1988;84(5):870–876.
   PubMed Web of Science ®Google Scholar
• Fukumoto S. Phosphate metabolism and vitamin D. Bonekey Rep. 2014;3:497.
   PubMedGoogle Scholar
• Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.
   PubMed Web of Science ®Google Scholar
• Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012;97(3):696–706.
   PubMed Web of Science ®Google Scholar
• Pasquali M, Tartaglione L, Rotondi S, et al. Calcitriol/calcifediol ratio: an indicator of vitamin D hydroxylation efficiency? BBA Clin. 2015;3:251–256.
   PubMedGoogle Scholar
• Penido MG, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012;27(11):2039–2048.
   PubMed Web of Science ®Google Scholar
• Prié D, Ureña Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009;75(9):882–889.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017;152(6):e5–e6.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Z, Shi Y, et al. Effect of hypophosphatemia on the withdrawal of mechanical ventilation in patients with acute exacerbations of chronic obstructive pulmonary disease. Biomed Rep. 2016;4(4):413–416.
   PubMed Web of Science ®Google Scholar
• Blazevic A, Hunze J, Boots JMM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72(1):49–53.
   PubMed Web of Science ®Google Scholar
• Fierz YC, Kenmeni R, Gonthier A, et al. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr. 2014;68(4):531–533.
   PubMed Web of Science ®Google Scholar
• Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017;2017:bcr2016219160.
   PubMedGoogle Scholar
• Ifie E, Oyibo SO, Joshi H, et al. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019(1):19-0065.
   Google Scholar
• Harris RE, Armstrong L, Curtis L, et al. Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease. Frontline Gastroenterol. 2019;11(4):324–326.
   PubMed Web of Science ®Google Scholar
• Vasquez-Rios G, Chapel A, Philip I, et al. Life-threatening hypophosphatemia following intravenous iron infusion. Nefrologia. 2020;S0211-6995(20):30071-0.
   Google Scholar
• Bart G, Glemarec J, Lerhun M, et al. A rusty man … or how iron can be responsible for bone pain. Symptomatic hypophosphataemic osteomalacia after iron carboxymaltose treatment. The Rheumatologist’s Newsletter. No. 428;2017.
   Google Scholar
• Burckhardt P. Iron-induced osteomalacia. Osteologie. 2018;27(1):20–23.
   Google Scholar
• Klein K, Asaad S, Econs M, et al. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018. DOI: https://doi.org/10.1136/bcr-2017-222851.
   Google Scholar
• Fragkos KC, Sehgal V, Rogers J, et al. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose – real world experience from a tertiary centre in the UK. GastroHep. 2020;2(5):205–214.
   Google Scholar
• Musgrove J, Wolf M. Regulation and effects of FGF23 in chronic kidney disease. Annu Rev Physiol. 2020;82(1):365–390.
   PubMedGoogle Scholar
• Baia LC, Heilberg IP, Navis G, et al. NIGRAM investigators. Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol. 2015;11(11):656–666.
   PubMed Web of Science ®Google Scholar
• Sari V, Atiqi R, Hoorn EJ, et al. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. Neth J Med. 2017;75(2):65–73.
   PubMed Web of Science ®Google Scholar
• Ferinject (ferric carboxymaltose). Prescribing information [Brazil]. Vifor (International) Inc; Sep 2020.
   Google Scholar
• GOV.UK. Drug safety update. Ferric carboxymaltose (Ferinject): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures. [cited 2020 Nov 16]. Available from: https://www.gov.uk/drug-safety-update/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures.
   Google Scholar
• Kang CK, Pope M, Lang CC, et al. Iron deficiency in heart failure: efficacy and safety of intravenous iron therapy. Cardiovasc Ther. 2017;35(6):e12301.
   Web of Science ®Google Scholar
• Cairo G, Bernuzzi F, Recalcati S. A precious metal: iron, an essential nutrient for all cells. Genes Nutr. 2006;1(1):25–39.
   PubMed Web of Science ®Google Scholar
• Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009;66(20):3241–3261.
   PubMed Web of Science ®Google Scholar
• Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med. 2016;2016:9152732.
   PubMedGoogle Scholar
• Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. CONFIRM-HF investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668.
   PubMed Web of Science ®Google Scholar
• Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Kirwan B-A, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904.
   PubMed Web of Science ®Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833–842.
   PubMed Web of Science ®Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306–315.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905–914.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Coyne DW. Data confusion. Kidney Int. 2015;88(6):1445.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Roger SD. New data on the safety of IV iron – but why the discrepancy with FIND-CKD? Kidney Int. 2015;88(6):1445–1446.
   PubMed Web of Science ®Google Scholar
• Charles-Edwards G, Amaral N, Sleigh A, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. Circulation. 2019;139(21):2386–2398.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC). NCT03662789. 2 Mar 2020.
   Google Scholar
• ClinicalTrials.gov. Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis (IIISAS). NCT04206228. 3 Apr 2020.
   Google Scholar
• ClinicalTrials.gov. Intravenous iron treatment in patients with heart failure and iron deficiency: IRONMAN (IRONMAN). NCT02642562. 6 Oct 2020.
   Google Scholar
• ClinicalTrials.gov. Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality (FAIR-HF2). NCT03036462. 8 May 2020.
   Google Scholar
• ClinicalTrials.gov. Randomized placebo-controlled trial of FCM as treatment for heart failure with iron deficiency (HEART-FID). NCT03037931. 3 Nov 2020.
   Google Scholar
• Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease (GBD) 2016. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Amarnani R, Travis S, Javaid MK. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology (Oxford). 2020;59(8):2166–2168.
   PubMed Web of Science ®Google Scholar
• CRYSVITA (burosumab). Summary of product characteristics. [cited 2020 Nov 4]. Available from: https://www.ema.europa.eu/en/documents/product-information/crysvita-epar-product-information_en.pdf
   Google Scholar